| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/21/2011 | US20110178125 Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| 07/21/2011 | US20110178122 Quinolizidinone M1 Receptor Positive Allosteric Modulators |
| 07/21/2011 | US20110178119 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase |
| 07/21/2011 | US20110178117 Oxazolobenzimidazole derivatives |
| 07/21/2011 | US20110178114 Topical regional neuro-affective therapy |
| 07/21/2011 | US20110178096 Octahydropentalene compounds as chemokine receptor antagonists |
| 07/21/2011 | US20110178094 Oral Formulation |
| 07/21/2011 | US20110178091 Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders |
| 07/21/2011 | US20110178090 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| 07/21/2011 | US20110178088 Tetrahydro-naphthalene derivatives |
| 07/21/2011 | US20110178086 Adamantyl diamide derivatives and uses of same |
| 07/21/2011 | US20110178083 Pde-10 inhibitors |
| 07/21/2011 | US20110178082 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/21/2011 | US20110178081 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/21/2011 | US20110178079 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 07/21/2011 | US20110178078 Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof |
| 07/21/2011 | US20110178075 Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| 07/21/2011 | US20110178073 Methods of improving cognitive functions |
| 07/21/2011 | US20110178069 Inhibitors of interleukin-1 beta converting enzyme |
| 07/21/2011 | US20110178068 Quaternary Ammonium Salt Prodrugs |
| 07/21/2011 | US20110178063 Benzpyrazol derivatives as inhibitors of pi3 kinases |
| 07/21/2011 | US20110178062 Indole and benzothiophene compounds as modulators of the histamine h3 receptor |
| 07/21/2011 | US20110178061 Heterocyclic derivatives for modulation of calcium channels |
| 07/21/2011 | US20110178060 Nitrogen-containing heterocyclic compound and use of same |
| 07/21/2011 | US20110178056 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| 07/21/2011 | US20110178055 Dual nk1/nk3 receptor antagonists |
| 07/21/2011 | US20110178050 Use of cyclolignans for the treatment of a hyperactive immune system |
| 07/21/2011 | US20110178047 Oxylipins From Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
| 07/21/2011 | US20110178044 Transdermal administration of hydrophilic drugs using permeation enhancer composition |
| 07/21/2011 | US20110178041 Heterocyclic biaryl derivative and pde inhibitor comprising same as active ingredient |
| 07/21/2011 | US20110178035 Method for obtaining pure monosialoganglioside gm1 for medical use |
| 07/21/2011 | US20110178032 Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders |
| 07/21/2011 | US20110178025 Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation |
| 07/21/2011 | US20110178024 Amyloid beta-peptides and methods of use thereof |
| 07/21/2011 | US20110178023 Use Of SCO-Spondin Peptides For Inhibiting Or Preventing Neuronal Apoptosis Mediated By Cell Death Receptor Ligands |
| 07/21/2011 | US20110178022 Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| 07/21/2011 | US20110178021 Opiorphin for use as a psychostimulant agent |
| 07/21/2011 | US20110178020 Methods and compositions for inhibition of neutrophil exocytosis |
| 07/21/2011 | US20110178009 Pheromones and the Luteinizing Hormone for Inducing Proliferation of Neural Stem Cells and Neurogenesis |
| 07/21/2011 | US20110178000 Apoptotically Active Peptides |
| 07/21/2011 | US20110177998 Bioactive peptides and methods of using same |
| 07/21/2011 | US20110177595 Multipotent Adult Stem Cells, Sources Thereof, Methods of Obtaining and Maintaining Same, Methods of Differentiation Thereof, Methods of Use Thereof and Cells Derived Thereof |
| 07/21/2011 | US20110177179 Preparation of botanical extracts containing absorbable components using pharmaceutical platform technology |
| 07/21/2011 | US20110177170 implantable neuroendoprosthetic system, a method of production thereof and a method of reconstructive neurosurgical operation |
| 07/21/2011 | US20110177168 Composition |
| 07/21/2011 | US20110177167 Hydrophilic/Lipophilic Polymeric Matrix Dosage Formulation |
| 07/21/2011 | US20110177165 Multiparticulate tablet and method for the production thereof |
| 07/21/2011 | US20110177159 Custom-formulated phospholipid microbubbles and methods and uses thereof |
| 07/21/2011 | US20110177158 Liposomes Capable of Effectively Binding the Beta Amyloid Peptide |
| 07/21/2011 | US20110177150 Implantable tissue compositions and method |
| 07/21/2011 | US20110177138 Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules |
| 07/21/2011 | US20110177137 Novel dosage form of paliperidone and process for preparing the same |
| 07/21/2011 | US20110177109 Antigenic tau peptides and uses thereof |
| 07/21/2011 | US20110177106 Novel Therapeutic Methods for Treating Inflammation and Immune System Disorders |
| 07/21/2011 | US20110177105 Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
| 07/21/2011 | US20110177094 Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
| 07/21/2011 | US20110177093 Use of bcma as an immunoregulatory agent |
| 07/21/2011 | US20110177086 Methods of antagonizing signal transduction in dorsal root ganglion cells |
| 07/21/2011 | US20110177083 Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| 07/21/2011 | US20110177076 Humanized anti-amyloid beta antibodies |
| 07/21/2011 | US20110177072 Methods of treating inflammation in neuronal tissue |
| 07/21/2011 | US20110177066 Prevention and treatment of amyloidogenic diseases |
| 07/21/2011 | US20110177061 Methods of treating and preventing neurological disorders using docosahexaenoic acid |
| 07/21/2011 | US20110177051 Methods and compositions for treatment of mitochondrial disorders |
| 07/21/2011 | US20110177046 Dithiazolidine and thiazolidine derivatives as anticancer agents |
| 07/21/2011 | US20110177041 Material for treatment of cerebral infarction and brain tissue regeneration method |
| 07/21/2011 | US20110176994 Buoyant Polymer Particles for Delivery of Therapeutic Agents to the Central Nervous System |
| 07/21/2011 | DE102010004986A1 New bromocriptine is prolactin inhibitor, useful for initiating, without concurrent medication, prolactin increase in male and female depressed patients for normalization of mood, and for treatment of reactive and endogenous depression |
| 07/21/2011 | DE102009025119B4 Antitumorale, antibiotische und insektizide Cyclodepsipeptide, deren Herstellung und Verwendungen Antitumoral, antibiotic and insecticidal cyclodepsipeptides, their preparation and uses |
| 07/21/2011 | CA2799474A1 Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring |
| 07/21/2011 | CA2790933A1 Stable dosage forms of levomilnacipran |
| 07/21/2011 | CA2786956A1 Compounds for the treatment of autism |
| 07/21/2011 | CA2786819A1 Method for titrating clozapine |
| 07/21/2011 | CA2786780A1 Compositions comprising andrographis paniculata and ginkgo biloba extracts complexed with phospholipids |
| 07/21/2011 | CA2786330A1 A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| 07/21/2011 | CA2785455A1 Tricyclic derivatives and their pharmaceutical use and compositions |
| 07/21/2011 | CA2785058A1 Tricyclic derivatives and their pharmaceutical use and compositions |
| 07/21/2011 | CA2785056A1 Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| 07/21/2011 | CA2784769A1 Novel substituted triazole derivatives as gamma secretase modulators |
| 07/21/2011 | CA2784765A1 Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| 07/21/2011 | CA2784007A1 Pyrrolidine derivatives |
| 07/20/2011 | EP2345722A1 Mutations in the parkin gene, compositions, methods and uses |
| 07/20/2011 | EP2345720A2 In vivo production of small interfering RNAs that mediate gene silencing |
| 07/20/2011 | EP2345715A2 Schwann cells originating in myeloid interstitial cells |
| 07/20/2011 | EP2345654A1 Eszopiclone particles and a process for their preparation |
| 07/20/2011 | EP2345649A1 Benzimidazole compound in crystal form and salt thereof |
| 07/20/2011 | EP2345639A1 Cyclic hydroxylamine derivatives, their preparation and use as antioxidants |
| 07/20/2011 | EP2345637A2 3, 10, and 12a substituted tetracycline compounds |
| 07/20/2011 | EP2345455A1 Lacosamide for the treatment of hyperexcitability disorder and diseases associated with sodium channel dysfunction |
| 07/20/2011 | EP2345418A1 Milk fat for the treatment of mucositis |
| 07/20/2011 | EP2345412A1 Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| 07/20/2011 | EP2345411A1 Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| 07/20/2011 | EP2344505A2 Indole and indoline derivatives and methods of use thereof |
| 07/20/2011 | EP2344501A1 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| 07/20/2011 | EP2344496A1 Amides of diazabicyclooctanes and uses thereof |
| 07/20/2011 | EP2344494A1 Aminotriazolopyridines and their use as kinase inhibitors |
| 07/20/2011 | EP2344493A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/20/2011 | EP2344492A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/20/2011 | EP2344486A2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof |
| 07/20/2011 | EP2344483A1 Compounds which have activity at m1 receptor and their uses in medicine |